Organization | Andalusian Network for Design and Translation of Advanced Therapies

Andalusian Network for Design and Translation of Advanced Therapies Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial

2020

NCT04366245

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2020

Timeline

NOW

Now

Alternative names

Andalusian Network for Design and Translation of Advanced Therapies

Active Ingredients

Drugs in Phase 2 Trials (7)

allogeneic adipose derived mesenchymal stem cell (1 trial)

azithromycin (zithromax) (1 trial)

COVID-19 convalescent plasma (1 trial)

hydroxychloroquine (plaquenil) (1 trial)

interferon beta-1b (betaseron) (1 trial)

lopinavir (Kaletra) (1 trial)

ritonavir (Norvir) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Infections (Phase 2)

Pneumonia (Phase 2)

Overview

Highest Phase: Phase 2
# of Trials: 2
# of Trial APIs: 7